TAG:
ameripath
AmeriPath Reports on 2003, Its First Year as a Private Firm
WILL BUSINESS BE BETTER for AmeriPath, Inc. as a private company than it was as a publicly-traded firm? Its 2003 financial report indicates some interesting challenges, many common to all laboratories. First, a look at basic numbers. AmeriPath’s net revenues grew from $478.8 milli…
IMPATH Has a Buyer: Genzyme Pays $215 Mil
CEO SUMMARY: Two unexpected things happened in IMPATH’s Chapter 11 bankruptcy action. First, it attracted a buyer willing to pay the premium price of $215 million for its assets. Second, the buyer was not another laboratory company. Rather, it is a new entrant into the oncology diagnost…
New Competitors Line Up In Oncology Marketplace
CEO SUMMARY: Local pathology groups are advised to more closely track developments in the national market for oncology testing. Not only is big money targeting cancer testing, but a number of nimble, entrepreneurial start-up companies have begun to compete for specimens. Genzyme’s acqui…
“February 2, 2004 Intelligence: Late Breaking Lab News”
Changes are afoot in the national market for anatomic pathology services. At AmeriPath, Inc., the search is on for a new CEO. Current Chairman and CEO, James C. New retired, effective February 1. The company has commenced the search for a new CEO. New had been with AmeriPath since it…
Who’s Buying Labs? Activity Shifts Down
CEO SUMMARY: As the number of independent clinical laboratories dwindles, most remaining owners seem content to continue building their business—at least until a buyer makes them an offer “they can’t refuse.” Acquisitions of pathology group practices were also few in number during…
2003’s Big Lab Stories Reflect Health Trends
CEO SUMMARY: At a minimum, 2003 proved to be a year of relative stability for the laboratory industry, as demonstrated by THE DARK REPORT’S “Ten Biggest Lab Stories of 2003.” The year was free of industry-wide crises and scan- dals. That allowed most laboratory administrators and pa…
Market Demand for Pathologists Shifts Toward Specialization
CEO SUMMARY: Unlike the slack employment market for pathologists seen during the 1990s, there is strong demand for pathologists in this decade. Private pathology group practices now face competition for the best pathology talent. That’s because public lab companies are regularly in the …
AP’s “High & Mighty” Firms Hit Tough Times
CEO SUMMARY: In the years between 1995 and 2002, public companies AmeriPath, DIANON Systems, and IMPATH built revenues and profits at a blistering pace. During this time period, these three firms captured enough market share to do almost $1 billion of anatomic pathology business in 2002. …
“July 7, 2003 Intelligence: Late Breaking Lab News”
Employers should brace for another round of higher health insurance costs. The early sign of more double-digit premium increases comes from California. Directors of CALPERS (California Public Employees Retirement System) voted to raise member HMO premiums by an average of between 16….
Lab Acquisitions in 2002 Changed National Market
NEVER IN THE PAST THREE DECADES has there been so few laboratory companies—public and private—competing to offer lab testing services to office-based physicians. At the end of 2002, THE DARK REPORT’S annual ranking of public laboratory companies showed just 11 firms. Of these, two (Uni…
CURRENT ISSUE
Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.